Structure-activity relationship for human cytochrome P450 substrates and inhibitors

Area of Science:

• Pharmacology
• Biochemistry
• Medicinal Chemistry

Background:

• Human hepatic cytochromes P450 (CYP) are critical enzymes in Phase 1 drug metabolism.
• Understanding substrate binding avidity is essential for predicting drug efficacy and interactions.
• Numerous CYP isoforms (e.g., CYP1A2, CYP2C9, CYP3A4) are involved in metabolizing a vast array of drugs.

Purpose of the Study:

• To describe the criteria governing substrate binding avidity to human hepatic CYPs.
• To elucidate the role of specific molecular properties in determining binding affinity.
• To provide quantitative structure-activity relationship (QSAR) insights for major drug-metabolizing CYPs.

Main Methods:

• Extensive quantitative structure-activity relationship (QSAR) analyses were performed.
• Substrates for key human CYP enzymes including CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 were analyzed.
• Molecular properties, with a focus on hydrogen bonding, were correlated with binding affinity.

Main Results:

• QSAR analyses revealed key factors influencing substrate binding avidity.
• Hydrogen bond properties were identified as particularly important determinants of binding affinity across various CYP-substrate complexes.
• Specific hydrogen bonding interactions significantly impact the strength of substrate binding to human drug-metabolizing CYPs.

Conclusions:

• Hydrogen bonding is a critical determinant of substrate binding affinity to human hepatic CYPs.
• These findings enhance our understanding of drug-enzyme interactions in Phase 1 metabolism.
• The QSAR insights can inform the rational design of new drugs with improved metabolic profiles and reduced drug-drug interactions.